Go Pro
→ The end may be near for these iconic stocks (From Chaikin Analytics) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Black Hawk Acquisition Corporation stock logo
BKHA
Black Hawk Acquisition
$12.41
+5.3%		$12.25
$10.93
▼
$13.10
$51.50M0.041,138 shs8,891 shs
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
$5.30
-1.1%		$6.56
$0.72
▼
$20.32
$51.04M1.082.03 million shs5,173 shs
LakeShore Biopharma Co., Ltd. stock logo
LSB
LakeShore Biopharma
$0.63
$0.70
$0.57
▼
$1.49
$13.02M0.56202,885 shsN/A
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
$0.77
+4.0%		$0.94
$0.72
▼
$2.57
$50.03M1.06716,758 shs38,355 shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Black Hawk Acquisition Corporation stock logo
BKHA
Black Hawk Acquisition
+0.69%+2.57%-12.66%+2.58%+13.24%
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
+2.49%+7.85%-28.53%-64.24%+136.12%
LakeShore Biopharma Co., Ltd. stock logo
LSB
LakeShore Biopharma
0.00%0.00%0.00%0.00%-13.58%
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
+1.81%-4.84%-30.52%-41.08%-56.93%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Black Hawk Acquisition Corporation stock logo
BKHA
Black Hawk Acquisition
$12.41
+5.3%		$12.25
$10.93
▼
$13.10
$51.50M0.041,138 shs8,891 shs
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
$5.30
-1.1%		$6.56
$0.72
▼
$20.32
$51.04M1.082.03 million shs5,173 shs
LakeShore Biopharma Co., Ltd. stock logo
LSB
LakeShore Biopharma
$0.63
$0.70
$0.57
▼
$1.49
$13.02M0.56202,885 shsN/A
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
$0.77
+4.0%		$0.94
$0.72
▼
$2.57
$50.03M1.06716,758 shs38,355 shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Black Hawk Acquisition Corporation stock logo
BKHA
Black Hawk Acquisition
+0.69%+2.57%-12.66%+2.58%+13.24%
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
+2.49%+7.85%-28.53%-64.24%+136.12%
LakeShore Biopharma Co., Ltd. stock logo
LSB
LakeShore Biopharma
0.00%0.00%0.00%0.00%-13.58%
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
+1.81%-4.84%-30.52%-41.08%-56.93%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Black Hawk Acquisition Corporation stock logo
BKHA
Black Hawk Acquisition
1.00
SellN/AN/A
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
2.67
Moderate Buy$5.00-6.72% Downside
LakeShore Biopharma Co., Ltd. stock logo
LSB
LakeShore Biopharma
0.00
N/AN/AN/A
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
2.33
Hold$6.00714.66% Upside

Current Analyst Ratings Breakdown

Latest LSB, EDSA, BKHA, and TCRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/17/2026
Black Hawk Acquisition Corporation stock logo
BKHA
Black Hawk Acquisition
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D)
7/17/2026
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
6/29/2026
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
Brookline Capital Markets logo
Brookline Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
6/24/2026
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
6/23/2026
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$5.00
6/23/2026
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
Needham & Company LLC logo
Needham & Company LLC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$6.00
(Data available from 8/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Black Hawk Acquisition Corporation stock logo
BKHA
Black Hawk Acquisition
N/AN/AN/AN/AN/AN/A
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
N/AN/AN/AN/A$0.45 per shareN/A
LakeShore Biopharma Co., Ltd. stock logo
LSB
LakeShore Biopharma
$85.67M0.15N/AN/A$3.35 per share0.19
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
$10.32M4.66N/AN/A$2.16 per share0.34
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Black Hawk Acquisition Corporation stock logo
BKHA
Black Hawk Acquisition
N/AN/AN/AN/AN/AN/AN/AN/AN/A
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
-$7.19M-$1.34N/AN/AN/AN/A-286.52%-75.36%8/14/2026 (Estimated)
LakeShore Biopharma Co., Ltd. stock logo
LSB
LakeShore Biopharma
-$13.93MN/AN/AN/AN/AN/AN/AN/AN/A
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
-$129.77M-$0.96N/AN/AN/A-1,360.61%-91.94%-50.15%8/11/2026 (Estimated)

Latest LSB, EDSA, BKHA, and TCRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2026N/A
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
-$0.44N/AN/AN/AN/AN/A
8/11/2026Q2 2026
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
-$0.29N/AN/AN/A$1.88 millionN/A
7/15/2026Q2 2026
Black Hawk Acquisition Corporation stock logo
BKHA
Black Hawk Acquisition
N/A$0.02N/A$0.02N/AN/A
5/14/2026Q2 2026
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
-$0.24-$0.49-$0.25-$0.49$0.05 millionN/A
5/6/2026Q1 2026
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
-$0.22-$0.22N/A-$0.22$2.50 million$0.98 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Black Hawk Acquisition Corporation stock logo
BKHA
Black Hawk Acquisition
N/AN/AN/AN/AN/A
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
N/AN/AN/AN/AN/A
LakeShore Biopharma Co., Ltd. stock logo
LSB
LakeShore Biopharma
N/AN/AN/AN/AN/A
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Black Hawk Acquisition Corporation stock logo
BKHA
Black Hawk Acquisition
N/AN/AN/A
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
N/A
4.76
4.76
LakeShore Biopharma Co., Ltd. stock logo
LSB
LakeShore Biopharma
0.05
1.02
0.75
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
0.34
6.65
6.65

Institutional Ownership

CompanyInstitutional Ownership
Black Hawk Acquisition Corporation stock logo
BKHA
Black Hawk Acquisition
N/A
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
5.50%
LakeShore Biopharma Co., Ltd. stock logo
LSB
LakeShore Biopharma
52.64%
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
82.83%

Insider Ownership

CompanyInsider Ownership
Black Hawk Acquisition Corporation stock logo
BKHA
Black Hawk Acquisition
N/A
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
24.40%
LakeShore Biopharma Co., Ltd. stock logo
LSB
LakeShore Biopharma
N/A
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
6.25%
CompanyEmployeesShares OutstandingFree FloatOptionable
Black Hawk Acquisition Corporation stock logo
BKHA
Black Hawk Acquisition
N/A4.15 millionN/AN/A
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
209.63 million7.28 millionNot Optionable
LakeShore Biopharma Co., Ltd. stock logo
LSB
LakeShore Biopharma
77320.77 millionN/AN/A
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
10065.35 million61.27 millionNot Optionable

Recent News About These Companies

Short Interest in TScan Therapeutics, Inc. (NASDAQ:TCRX) Expands By 95.5%
July 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/short-interest-in-tscan-therapeutics-inc-nasdaqtcrx-expands-by-955-2026-07-30/
TScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2™, a Pivotal Trial Evaluating TSC-101 in Patients with Heme Malignancies
July 29, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/29/3335095/0/en/tscan-therapeutics-announces-first-patient-dosed-in-phase-3-alloha-2-a-pivotal-trial-evaluating-tsc-101-in-patients-with-heme-malignancies.html
TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives Consensus Rating of "Hold" from Analysts
July 19, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/tscan-therapeutics-inc-nasdaqtcrx-receives-consensus-rating-of-hold-from-analysts-2026-07-19/
TScan Therapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
June 24, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/24/3316713/0/en/tscan-therapeutics-to-participate-in-the-h-c-wainwright-4th-annual-cell-therapy-virtual-conference.html
TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic ...
June 23, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/tscan-therapeutics-announces-positive-initial-data-from-cohort-c-of-ongoing-alloha-phase-1-study-evaluating-tsc-101-in-patients-with-heme-malignancies-undergoing-allogeneic-hematopoietic-cell-1036264745
TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation
June 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/22/3315162/0/en/tscan-therapeutics-announces-positive-initial-data-from-cohort-c-of-ongoing-alloha-phase-1-study-evaluating-tsc-101-in-patients-with-heme-malignancies-undergoing-allogeneic-hematop.html
Cellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic Malignancies
June 3, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260603703141/en/cellares-and-tscan-therapeutics-announce-agreement-to-evaluate-automated-manufacturing-of-tsc-101-for-patients-with-hematologic-malignancies/
TScan Therapeutics, Inc. (TCRX) Reports Q1 2026 Results With Improved Net Loss
June 2, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/blog/tscan-therapeutics-inc-tcrx-reports-q1-2026-results-with-improved-net-loss-1773515/
TScan Therapeutics Expands Authorized Shares After Stockholder Vote
May 22, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/tscan-therapeutics-expands-authorized-shares-after-stockholder-vote?utm_source=marketbeat.com&utm_medium=referral
TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Lags Revenue Estimates
May 6, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2915585/tscan-therapeutics-inc-tcrx-reports-q1-loss-lags-revenue-estimates?cid=cs-stocknewsapi-ft-tale_of_the_tape|yseop_template_4-2915585
TScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 6, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/06/3288637/0/en/tscan-therapeutics-reports-first-quarter-2026-financial-results-and-provides-corporate-update.html
TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 29th Annual Meeting
April 27, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/27/3282046/0/en/tscan-therapeutics-announces-upcoming-presentation-at-the-american-society-of-gene-and-cell-therapy-29th-annual-meeting.html
Why TScan Therapeutics, Inc.’s (TCRX) Stock Is Up 7.40%
April 18, 2026  |  aaii.comA
TScan Therapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference
April 8, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/08/3269963/0/en/tscan-therapeutics-to-participate-in-the-25th-annual-needham-virtual-healthcare-conference.html
TScan Therapeutics Consolidates Finance Leadership After Officer Resignation
April 2, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/tscan-therapeutics-consolidates-finance-leadership-after-officer-resignation?utm_source=marketbeat.com&utm_medium=referral
Strong Analyst Sentiment on TScan Therapeutics (TCRX) Amid Ongoing Momentum in Cell Therapy Space
March 25, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/blog/strong-analyst-sentiment-on-tscan-therapeutics-tcrx-amid-ongoing-momentum-in-cell-therapy-space-1724848/
TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Misses Revenue Estimates
March 4, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2878454/tscan-therapeutics-inc-tcrx-reports-q4-loss-misses-revenue-estimates?cid=cs-stocknewsapi-ft-tale_of_the_tape|yseop_template_4-2878454
TScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
March 4, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/03/04/3249222/0/en/tscan-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update.html
TScan Therapeutics Completes Enrollment in Cohort C of Phase 1 ALLOHA™ Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102 ...
February 26, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/tscan-therapeutics-completes-enrollment-in-cohort-c-of-phase-1-alloha-trial-and-announces-fda-clearance-of-investigational-new-drug-applications-for-heme-candidates-tsc-102-a01-and-tsc-102-a03-1035871680
TScan Therapeutics Completes Enrollment in Cohort C of Phase 1 ALLOHA™ Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A01 and TSC-102-A03
February 26, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/02/26/3245412/0/en/tscan-therapeutics-completes-enrollment-in-cohort-c-of-phase-1-alloha-trial-and-announces-fda-clearance-of-investigational-new-drug-applications-for-heme-candidates-tsc-102-a01-and.html
TScan Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference
February 25, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/02/25/3244454/0/en/tscan-therapeutics-to-participate-in-the-td-cowen-46th-annual-health-care-conference.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Black Hawk Acquisition stock logo

Black Hawk Acquisition NASDAQ:BKHA

$12.41 +0.63 (+5.35%)
As of 09:30 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Black Hawk Acquisition Corporation focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2023 and is based in Danville, California.

Edesa Biotech stock logo

Edesa Biotech NASDAQ:EDSA

$5.30 -0.06 (-1.12%)
As of 09:59 AM Eastern

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.

LakeShore Biopharma stock logo

LakeShore Biopharma NASDAQ:LSB

LakeShore Biopharma Co., Ltd. engages in the provision of discovering, developing, manufacturing, and commercializing vaccines and therapeutic biologics for infectious diseases and cancer. It focuses on developing PIKA technology platform. It operates through the People's Republic of China and Other Countries or Regions. The company was founded by Yi Zhang on November 16, 2020 and is headquartered in Beijing, China.

TScan Therapeutics stock logo

TScan Therapeutics NASDAQ:TCRX

$0.77 +0.03 (+3.95%)
As of 10:02 AM Eastern

TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas